Anti-TA-MUC1 monoclonal antibody - Glycotope

Drug Profile

Anti-TA-MUC1 monoclonal antibody - Glycotope

Alternative Names: GlycoOptimised IgG1 antibody - Glycotope; GT-MAB 2.5-GEX™; PankoMab; PankoMab-GEX

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NEMOD Biotherapeutics [CEASED]
  • Developer Glycotope
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Mar 2016 Anti-TA-MUC1 monoclonal antibody is still in phase II trials in Ovarian cancer (Recurrent, Maintenance therapy) in Germany, Hungary, Italy, Poland, Romania, Russia, Spain and United Kingdom (IV)
  • 23 Jan 2014 Phase-II clinical trials in Ovarian cancer (Recurrent, Maintenance therapy) in Germany, Italy, Poland, Romania, Russia, Spain and United Kingdom (IV)
  • 16 Oct 2013 Adverse events, efficacy and pharmacokinetic data from a phase I trial in Solid Tumours released by Glycotope
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top